Nov 5 (Reuters) - AstraZeneca (AZN.L), opens new tab shares on Tuesday recorded their worst day since March 2020 after a report that dozens of the drugmaker's senior executives in China could be ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

The U.K. pharmaceutical company AstraZeneca has become the largest multinational drugmaker in China, drawing 13% of its $5.8 billion in revenue last year from there, against a backdrop of an acute ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD.

A fraud investigation linked to AstraZeneca (NASDAQ:AZN) has expanded to several government agencies, implicating dozens of senior executives at the company as of last week, Shanghai-based ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, which it hopes could offer an alternative to current injectable drugs used to lower cholesterol. The new ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca Plc said its experimental obesity pill was well tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines. The ...

AstraZeneca (LSE: AZN) has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. Among the ...